NEW YORK – A subset of tumors from a rare, metastasis-prone subtype of pancreatic cancer known as adenosquamous carcinoma may be susceptible to treatments that target FGFR and other pathways identified through genomic and chromatin profiling, according to findings from investigators at the Mayo Clinic and elsewhere.